Psychosocial determinants and outcomes of chemotherapy in older women with breast cancer: What do we know? What do we need to know?

Cancer Journal

Volumn 11, Issue 6, 2005, Pages 518-528

  Tallarico, Michelle ^a,b   Figueiredo, Melissa ^a,b   Goodman, Michelle ^a,b   Kreling, Barbara ^a,b   Mandelblatt, Jeanne ^a,b  

^a Georgetown University Medical Center ^*

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Breast neoplasm; Chemotherapy; Elderly; Older women; Quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; DOCTOR PATIENT RELATION; EMOTIONAL STRESS; FUNCTIONAL STATUS; HUMAN; INTERPERSONAL COMMUNICATION; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW;

ADAPTATION, PSYCHOLOGICAL; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS; QUALITY OF LIFE; UNITED STATES;

EID: 30744437436     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200511000-00011     Document Type: Review

References (102)

1. Jemal A, Murray T, Ward E et al. Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Ries LA, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
3. U.S. Census Bureau. Statistical Abstract of the United States. The National Data Book. Washington, DC: Department of Commerce, 1998.
4. Lash TL, Silliman RA. Re: revalence of cancer. J Natl Cancer Inst 1998;90:399-400.
5. Mandelblatt JS, Bierman AS, Gold K et al. Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res 2001;36[suppl 6, pt 1]:1085-1107.
6. Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer 1993;72:594-601.
7. Greenfield S. Patterns of care related to age of breast cancer patients. JAMA 1987;257:2766-2770.
8. Newschaffer CJ, Penberthy L, Desch CE et al. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996;156: 85-90.
9. Schrag D, Cramer LD, Bach PB et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-857.
10. Silliman RA, Guadagnoli E, Weitberg AB et al. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 1989;44:M46-M50.
11. Goodwin JS. Factors affecting the diagnosis and treatment of older persons with cancer. In: Balducci L, Lyman GH, Ershler WB et al, eds. Comprehensive Geriatric Oncology. London: Harwood Academic Publishers; 1998:115-121.
12. Samet JM, Hunt WC, Key C et al. Choice of cancer therapy varies with age of patient. JAMA 1986;255:3385-3390.
13. Turner NJ, Haward RA, Mulley GP et al. Cancer in old age-is it inadequately investigated and treated? BMJ 1999;319:309-312.
14. Yancik R, Wesley M, Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
15. Hadley J, Mandelblatt JS, Mitchell JM et al. Medicare breast surgery fees and treatment received by older women with localized breast cancer. Health Serv Res 2003;38:553-573.
16. Mariotto A, Feuer EJ, Harlan LC et al. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002; 94:1626-1634.
17. Guadagnoli E, Shapiro C, Gurwitz JH et al. Age-related patterns of care: evidence against ageism in the treatment of early stage breast cancer. J Clin Oncol 1997;15:2338-2344.
18. Buchner DM, Wagner EH. Preventing frail health. Clin Geriatr Med 1992;8:1-17.
19. Mandelblatt J, Eisenberg JM. Historical and methodological perspectives on cancer outcomes research. Oncology (Williston Park) 1995;9[suppl 11]:23-32.
20. Patrick DL, Erickson P. Health Status and Heath Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press; 1993.
21. Drummond MF, Stoddardt GL, Torrance GW, eds. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press; 1987.
22. Fallowfield LJ, Hall A, Maguire GP et al. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. BMJ 1990;301:575-580.
23. Ershler WB, Longo LD. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 1997;89:1489-1497.
24. Mandelblatt JS, Edge SB, Meropol NJ et al. Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J Clin Oncol 2003;21:855-863.
25. Lantz PM, Ubel PA. The use of life expectancy in cancer screening guidelines. Moving with caution from model-based evidence to evidence-based guidelines. J Gen Intern Med 2005;20:552-553.
26. Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-1081.
27. Ganz PA. Quality of life measures in cancer chemotherapy methodology and implications. PharmacoEcon 1994;5:376-388.
28. Bottomley A, Therasse P. Quality of life in patients undergoing systemic treatment for advanced breast cancer. Lancet Oncol. 2002;3:620-628.
29. Crivellari D, Bonetti M, Castiglione-Gertsch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-1422.
30. Gennari R, Curigliano G, Rotmensz N et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger post-menopausal patients. Cancer 2004;101:1302-1310.
31. Maisano R, Mare M, Caristi N et al. A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study. J Chemother 2005;17:242-246.
32. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2161.
33. ten Tije AJ, Smorenburg SC, Seynaeve C et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004;40:352-357.
34. Hess D, Thurlimann B, Pagani O et al. Capecitabine and vinorelbine in elderly patients (> or = 65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 2004; 15:1760-1765.
35. Minisini A, Spazzapan S, Crivellar D et al. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors. Crit Rev Oncol Hematol 2005;53:125-131.
36. Pierga JY, Girre V, Laurence V et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004;13:369-375.
37. Vogel C, O'Rourke M, Winer E et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999;10:397-402.
38. Gupta S, Mauer AM, Ryan CW et al. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am J Orthopsychiatry 2005;28:65-69.
39. Del Mastro L Perrone F, Repetto L et al. Weekly paclitaxel as first-line chemoterapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italionao di Oncolgia Geriatrica (GIOGer). Ann Oncol 2005;16:253-258.
40. D'hondt R, Paridaens R, Wildiers H. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 2004;15: 341-346.
41. Freyer G, Lortholary A, Delcambre C et al. Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience. Clin Oncol (R Coll Radiol) 2004;16:17-23.
42. Dinota A, Bilancia D, Romano R et al. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer. Breast Cancer Res Treat 2005; 89:1-3.
43. Hainsworth JD, Burris HA, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500-3505.
44. Given CW, Given B, Azzouz F et al. Predictors of pain and fatigue in the year following diagnosis among elderly cancer patients. J Pain Symptom Manage 2001;21:456-446.
45. Guralnik JM, LaCroix AZ, Everett DF et al. Aging in the eighties: the prevalence of comorbidity and its association with disability. Advance Data from Vital and Health Statistics, No. 170. Hyattsville, MD: National Center for Health Statistics; 1989.
46. Goodwin JS, Samet JM, Hunt WC. Determinants of survival in older cancer patients. J Natl Cancer Inst 1996;88:1301-1338.
47. Satariano WA, Ragheb N., Dupuis ME. Comorbidity in older women with breast cancer: an epidemiological approach In: Yancik R, Yates JW, eds. Cancer in the Elderly: Approaches to Early Detection and Treatment. New York: Springer; 1989:71-107.
48. Broeckel JA. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998;6: 1689-1696.
49. Silliman RA, Prout MN, Field T et al. Risk factors for a decline in upper body function following the treatment for early stage breast cancer._Breast Cancer Res_Treat 1999;54:25-30.
50. Williams ME. Identifying the older person likely to require long-term service. J Am Geriatr Soc 1987;34:761-766.
51. Satariano WA, Ragland DR, DeLorenze GN. Limitations with upper-body strength associated with breast cancer: a comparison of black and white women. J Clin Epidemiol 1996;49: 5 535-544.
52. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
53. Feliu J, Lopez Gomez L, Madronal C et al. Gemcitabine plus vinorelbine in non-small cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer 1999;86:1463-1469.
54. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345-1091-1097.
55. Extermann M, Chen H, Cantor AB et al. Predictors of tolerance to chemotherapy in older patients: a prospective pilot study. Eur J Cancer 2002;38:1466-1473.
56. Fox S, Tsou CV, Klos DS. An intervention to increase mammography screening by residents in family practice. J Fam Pract 1985;20:467-471.
57. Goodwin JS. Knowledge about aging among physicians. J Aging Health 1989;1:234-243.
58. Recht A, Hayes D, Eberlein TJ, et al. Local-regional recurrence after mastectomy or breast conserving therapy. In: Harris JR, Lippman ME, Morrow M et al, eds. Diseases of the Breast. Philadelphia, PA: Lippincott-Raven; 1996.
59. Lyman GH, Lyman S, Balducci L et al. Age and the risk of breast cancer recurrence. Cancer Control 1996;3:421-427.
60. Shechter M, Zeidner M. Anxiety: towards a decision-theoretic perspective. Br J Math Stat Psychol 1990;43:15-28.
61. Mor V, Malin M, Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr 1994;16:191-197.
62. Silliman RA, Dukes KA, Sullivan LM et al. Breast cancer care in older women: sources of information, social support, and emotional health outcomes. Cancer 1998;83:706-711.
63. Vlek C. Risk assessment, risk perception and decision making about courses of action involving genetic risk: an overview of concepts and methods. Birth Defects Orig Artic Ser 1987;23: 171-207.
64. Ciampi A, Silberfeld M, Till JE. Measurement of individual preferences: the importance of "situation-specific" variables. M ed Decis MAking 1982;2:483-495.
65. Yellen SB, Cella DF. Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 1995;13:1255-1264.
66. Beisecker AE, Cook MR, Ashworth J et al. Side effects of adjuvant chemotherapy: perceptions of node-negative breast cancer patients. Psycho-Oncology 1997;6:85-93.
67. Schagen SB, van Dam FS, Muller MJ et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-650.
68. van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218.
69. Breast Cancer Resource Center at Pinkribbon.com. Chemobrain. http://www.pinkribbon.com/chemobrain.htm, 2000.
70. Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20:485-493.
71. Cimprich B. Age and extent of surgery affect attention in women treated for breast cancer. Res Nurs Health 1998;21: 229-238.
72. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000;64:165-176.
73. McQuellon RP. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995;13:858-868.
74. Llewellyn-Thomas HA, Naylor CD, O'Connor AM. Eliciting patient preferences. Ann Intern Med 1993;118:76.
75. McNeil BJ, Pauker SG, Sox HC Jr et al. On the elicitation of preferences for alternative therapies. N Engl J Med 1982;306: 1259-1262.
76. Till JE, Sutherland HJ, Meslin EM. Is there a role for preference assessments in research on quality of life in oncology? Qual Life Res 1992;1:31-40.
77. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458-1460.
78. Detmar SB, Aaronson NK, Wever LD et al. How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. J C Clin Oncol 2000;18:3295-3301.
79. Maly RC, Leake B, Silliman RA. Health care disparities in older patients with breast carcinoma: informational support from physicians. Cancer 2003;97:1517-1527.
80. Siminoff LA, Fetting JH, Abeloff MD. Doctor-patient communication about breast cancer adjuvant therapy. J Clin Oncol 1 1989;7:1192-1200.
81. Mandelblatt JS, Hadley J, Kerner JE et al. Patterns of breast cancer treatment in the elderly: patient, physician, and medical system influences. Cancer 2000;89:561-573.
82. Kearney N, Miller M, Paul J et al. Oncology healthcare professionals' attitudes toward elderly people. Ann Oncol 2000; 11:599-601.
83. Radecki SE, Kane RL, Solomon DH et al. Do physicians spend less time with older patients? J Am Geriatr Soc 1998;36:713-718.
84. Keeler EB, Solomon DH, Beck JC et al. Effect of patient age on duration of medical encounters with physicians. Med Care 1982;20:1101-1108.
85. Greene MG, Adelman RD, Rizzo C. Problems in communication between physicians and older patients. J Geriatr Psychiatry 1996;29:13-32.
86. O'Connor AM. Effects of framing and level of probability on patients' preferences for cancer chemotherapy. J Clin Epidemiol 1989;42:119-126.
87. Cassileth BR, Zupkis RV, Sutton-Smith K et al. Information and participation preferences among cancer patients. Ann Intern Med 1980;92:832-836.
88. Yabroff K, Rubenstein LE, Gold K. Information framing in physician description of treatment options for cancer patients [abstract]. Med Decis Making 1995;15:432a.
89. Daugherty C, Ratain MJ, Grochowski E et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 1995;13:1062-1072.
90. Penman DT, Holland JC, Bahna GF et al. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol 1984;2:849-855.
91. Street RL Jr, Voigt B. Patient participation in deciding breast cancer treatment and subsequent quality of life. Med Decis Making 1997;17:298-306.
92. Morris J, Ingham R. Choice of surgery for early breast cancer: psychosocial considerations. Soc Sci Med 1988;27:1257-1262.
93. Kaplan SH, Greenfield S, Ware JE. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care 1989;27:S110-S127.
94. Simes RJ, Cocker K, Glaszious P et al. Costs and benefits of adjuvant chemotherapy for breast cancer: an assessment of patient preferences [abstract]. Proc Am Soc Clin Oncol 1989; 8:52.
95. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998;16:515-521.
96. Bouchardy C, Rapiti E, Fioretta G et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003;21:3580-3587.
97. Satariano WA, Ragland DR. Upper-body strength and breast cancer: a comparison of the effects of age and disease. J Gerontol A Biol Sci Med Sci 1996;51:M215-M219.
98. Velanovich V, Gabel M, Walker EM et al. Causes for the undertreatment of elderly breast cancer patients: tailoring treatments to individual patients. J Am Coll Surg 2002;194:8-13.
99. Blackman SB, Lash TL, Fink AK et al. Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients. Cancer 2002;95:2465-2472.
100. Firat S, Gore E, Byhardt RW. Do "elderly fit" patients have less comorbidity? Int J Radiat Oncol Biol Phys 2003;55:1166-1168.
101. Lash TL, Thwin SS, Horton NJ. Multiple informants: a new method to assess breast cancer patients' comorbidity. Am J Epidemiol 2003;157:249-257.
102. Fleming ST, Rastogi A, Dmitrienko A et al. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 1999;37:601-614.